FreeTheAI

FDA Approves Ryzumvi Label Expansion for Opus Genetics and Viatris

BullishMedium impact
IRD$3.91 −3.46%VTRS$18.41 1.02%

Opus Genetics (IRD) and commercial partner Viatris (VTRS) have secured U.S. Food and Drug Administration approval to broaden the use of Ryzumvi. The eye care solution, also known as phentolamine ophthalmic solution, is now cleared to treat adults with presbyopia, an age-related loss of clear close-up vision.

The decision follows positive data from two Phase 3 clinical trials, VEGA-2 and VEGA-3, which met all primary and key secondary effectiveness goals with a favorable safety record. Before this label expansion, the drug was approved in the U.S. only for reversing pupil dilation in patients three years of age and older. The approval also triggers a milestone payment to Opus Genetics under its 2022 licensing and collaboration deal with Viatris.

Moving forward, investors will watch for details on the milestone payment amount and timeline. Attention will also turn to the joint commercial rollout for presbyopia in the U.S. and select international markets covered by the agreement.

Key points

  • The FDA approved a label expansion for Ryzumvi to treat adults with presbyopia, an age-related loss of close-up vision.
  • The treatment, developed by Opus Genetics (IRD) and Viatris (VTRS), was previously approved only for pupil dilation.
  • Approval was supported by positive Phase 3 results from the VEGA-2 and VEGA-3 clinical trials.
  • The decision triggers a milestone payment to Opus Genetics under its 2022 commercial agreement with Viatris.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is Ryzumvi approved for?

The FDA approved Ryzumvi to treat adults with presbyopia, an age-related condition causing loss of clear close-up vision. It was previously approved in the U.S. to treat dilated pupils in patients aged three and older.

Who markets Ryzumvi?

Ryzumvi is marketed jointly by Opus Genetics and Viatris under a 2022 licensing and collaboration agreement.

What does the FDA decision mean for Opus Genetics?

The approval triggers a milestone payment to Opus Genetics from Viatris under their existing partnership agreement.